To synthesize and critically evaluate the emerging evidence linking histamine intolerance to fibromyalgia, focusing on specific mechanisms of pain generation and amplification.
Key Findings:
74.5% prevalence of DAO deficiency-associated genetic variants in fibromyalgia patients vs. 66% in the general population (p = 0.014).
Cumulative variants correlate with increased symptom severity (∼7-point FIQ increase per allele).
DAO supplementation in a randomized controlled trial showed significant improvements in pain and fibromyalgia impact scores (p < 0.003).
29% fibromyalgia prevalence among chronic pruritus patients; odds ratios of 1.30–2.50 for allergic comorbidities among fibromyalgia patients, indicating a notable association.
Interpretation:
Evidence supports the need for systematic histamine intolerance assessment in fibromyalgia patients, particularly those with gastrointestinal symptoms, chronic pruritus, or treatment resistance, highlighting its potential impact on clinical management.
Limitations:
Need for larger multicenter replication studies to confirm findings.
Lack of standardized diagnostic protocols for histamine intolerance, which may hinder accurate diagnosis and treatment.
Conclusion:
This review provides a practical clinical framework for identifying and managing a potentially treatable fibromyalgia subtype linked to histamine intolerance.
